Update from HER2CLIMB in Relapsed Refractory HER2-Positive Breast Cancer

home / news-network / update-from-her2climb-in-relapsed-refractory-her2-positive-breast-cancer

Implications for treating patients with progressive, unresectable locally advanced or metastatic HER2-positive breast cancer with tucatinib in combination with capecitabine and trastuzumab.

breast oncologist

EP. 1: Standard of Care for R/R Metastatic HER2+ Breast Cancer

September 8th 2021

Current treatment options and outcomes for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy, with special insight regarding the management of brain metastasis and visceral disease.

breast oncologist

EP. 2: HER2+ Breast Cancer: Key Takeaways From HER2CLIMB

September 8th 2021

An overview of the latest data demonstrated by the HER2CLIMB study evaluating the efficacy and safety of tucatinib in combination with capecitabine and trastuzumab for patients with relapsed/refractory metastatic HER2-positive breast cancer.

breast oncologist

EP. 3: R/R Metastatic HER2+ Breast Cancer Treatment Considerations

September 8th 2021

Factors that impact treatment selection for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy.

breast oncologist

EP. 4: Future Opportunities With Novel Therapies for HER2+ Breast Cancer

September 8th 2021

Novel therapies that show promise in addressing treatment gaps in HER2-positive breast cancer, and exciting data that are expected to be reported on at the upcoming ESMO 2021 meeting.